Pracinostat

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Oral bioavailability in mice is 34%.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

404 Data

Ivabradine	Ivabradine may increase the QTc-prolonging activities of Pracinostat.
Vorinostat	The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Pracinostat is combined with Vorinostat.
Dofetilide	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Dofetilide.
Citalopram	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Citalopram.
Anagrelide	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Anagrelide.
Disopyramide	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Disopyramide.
Clemastine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Clemastine.
Ibutilide	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Ibutilide.
Valproic acid	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Valproic acid.
Terfenadine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Terfenadine.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Grepafloxacin.
Quinine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Quinine.
Sotalol	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Sotalol.
Erlotinib	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Erlotinib.
Toremifene	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Toremifene.
Cisapride	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Cisapride.
Imatinib	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Imatinib.
Astemizole	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Astemizole.
Thioridazine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Thioridazine.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Trovafloxacin.
Mifepristone	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Mifepristone.
Cocaine	The risk or severity of methemoglobinemia can be increased when Pracinostat is combined with Cocaine.
Quinidine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Quinidine.
Procainamide	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Procainamide.
Pimozide	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Pimozide.
Amiodarone	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Amiodarone.
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Arsenic trioxide.
Escitalopram	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Escitalopram.
Domperidone	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Domperidone.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Sparfloxacin.
Halofantrine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Halofantrine.
Bepridil	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Bepridil.
Paliperidone	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Paliperidone.
Lithium cation	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Lithium cation.
Temafloxacin	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Temafloxacin.
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Zuclopenthixol.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Tetrabenazine.
Dronedarone	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Dronedarone.
Nilotinib	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Nilotinib.
Iloperidone	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Iloperidone.
Vandetanib	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Vandetanib.
Romidepsin	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Romidepsin.
Asenapine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Asenapine.
Artemether	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Artemether.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Lumefantrine.
Vemurafenib	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Vemurafenib.
Eliglustat	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Eliglustat.
Ribociclib	The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Pracinostat.
Glasdegib	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Glasdegib.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Deutetrabenazine.
Macimorelin	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Macimorelin.
Terodiline	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Terodiline.
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pracinostat.
Goserelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pracinostat.
Erythromycin	The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Pracinostat.
Azithromycin	The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Pracinostat.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pracinostat.
Ranolazine	The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Pracinostat.
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Pracinostat.
Amitriptyline	The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Pracinostat.
Methadone	The risk or severity of QTc prolongation can be increased when Methadone is combined with Pracinostat.
Diltiazem	The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Pracinostat.
Clozapine	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Clozapine.
Sulpiride	The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Pracinostat.
Nimodipine	The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Pracinostat.
Promazine	The risk or severity of QTc prolongation can be increased when Promazine is combined with Pracinostat.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Pracinostat.
Droperidol	The risk or severity of QTc prolongation can be increased when Droperidol is combined with Pracinostat.
Imipramine	The risk or severity of QTc prolongation can be increased when Imipramine is combined with Pracinostat.
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Pracinostat.
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pracinostat.
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Pracinostat.
Fluorouracil	The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Pracinostat.
Perflutren	The risk or severity of QTc prolongation can be increased when Perflutren is combined with Pracinostat.
Cinnarizine	The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Pracinostat.
Atropine	The risk or severity of QTc prolongation can be increased when Atropine is combined with Pracinostat.
Chloroquine	The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Pracinostat.
Efavirenz	The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Pracinostat.
Adenosine	The risk or severity of QTc prolongation can be increased when Adenosine is combined with Pracinostat.
Pentamidine	The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Pracinostat.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Pracinostat.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Pracinostat.
Dolasetron	The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Pracinostat.
Roxithromycin	The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Pracinostat.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Pracinostat.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Pracinostat.
Loperamide	The risk or severity of QTc prolongation can be increased when Loperamide is combined with Pracinostat.
Granisetron	The risk or severity of QTc prolongation can be increased when Granisetron is combined with Pracinostat.
Ondansetron	The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Pracinostat.
Levosimendan	The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Pracinostat.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Pracinostat.
Desloratadine	The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Pracinostat.
Telithromycin	The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Pracinostat.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Pracinostat.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Pracinostat.
Primaquine	The risk or severity of QTc prolongation can be increased when Primaquine is combined with Pracinostat.
Papaverine	The risk or severity of QTc prolongation can be increased when Papaverine is combined with Pracinostat.
Chlorpheniramine	The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Pracinostat.
Nifedipine	The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Pracinostat.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Pracinostat.

Target Protein

Histone deacetylase 1 HDAC1

Histone deacetylase 2 HDAC2

Histone deacetylase 3 HDAC3

Histone deacetylase 6 HDAC6

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual